Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04045470 · ClinicalTrials.gov registry record · NA
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
A NA study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04045470: Recruiting NA study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, sponsored by Dana-Farber Cancer Institute.
NCT04045470 is a NA study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04045470, a NA study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma
Primary Outcome
"Failure" will be considered any of the following: 1. Any grade 3 or 4 adverse events associated with device placement or retrieval 2. Any device resulting in "major" adverse events as listed below: * device unable to be found or unable to be retrieved * device invading into vessel or device embolism * infection or severe tissue damage or abnormal wound healing associated with device or procedure (as deemed by a neutral consultant e.g. dermatologist, ID specialist or surgeon) * sev
Conditions Studied
Interventions
- DEVICE Microdevices
- OTHER Standard of care therapy
- OTHER Standard of care systemic therapy
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT04045470 shows while recruiting
NCT04045470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Microdevices is the first listed.
NCT04045470 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04045470 about?
NCT04045470 is a clinical study titled "A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma". This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphom...
What is the current status of trial NCT04045470?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2019-12-11. Estimated completion is 2027-01-01.
What conditions does trial NCT04045470 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Cutaneous T Cell Lymphoma.
What interventions are being tested in trial NCT04045470?
The interventions under investigation include: Microdevices (DEVICE), Standard of care therapy (OTHER), Standard of care systemic therapy (OTHER).
Who is sponsoring clinical trial NCT04045470?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04045470 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04045470's enrollment target sits among peer trials
20 26th of 34 higher than 7 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
RECRUITING
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
RECRUITING · Early Phase 1
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI